← Eichor
Condition: Leukemia Lymphoma Adult T Cell Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Leukemia Lymphoma Adult T Cell

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign
EARLY_Phase 1 · 1 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT07312630Novel Therapeutic Approach for Human T-cell Malignancies
Phase N/A · 2 location(s) · Istituto Oncologico Veneto IRCCS · NCT06600568Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Phase 1 · 1 location(s) · Stephan Grupp MD PhD · NCT06934382A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies W
Phase N/A · 3 location(s) · National Cancer Institute (NCI) · NCT05237986CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A
Phase 2 · 2 location(s) · KK Women's and Children's Hospital · NCT05648019NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05277753Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Phase 1 · 1 location(s) · Belarusian Research Center for Pediatric Oncology, Hematolog · NCT05333302Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic L
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT00501826Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic
Phase 1/Phase 2 · 2 location(s) · Gyala Therapeutics · NCT07471789AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06633354HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
Phase 3 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT07203352Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosom
Phase 2 · 1 location(s) · University of Washington · NCT07224100CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
Phase 1 · 1 location(s) · National University Hospital, Singapore · NCT05043571A Phase I Dose Finding Study of MB-CART2219.1
Phase 1 · 2 location(s) · University Hospital Tuebingen · NCT07108868Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07159620Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Phase 1 · 1 location(s) · Stanford University · NCT06408194Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04033302A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Phase 3 · 5 location(s) · Memorial Sloan Kettering Cancer Center · NCT07223021Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relaps
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05751044Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Evaluation of Patients With HAM/TSP
Phase N/A · 1 location(s) · National Institute of Neurological Disorders and Stroke (NIN · NCT00001778HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Rela
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05745714CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
Phase 2 · 1 location(s) · St. Jude Children's Research Hospital · NCT06847269Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
Phase 1 · 1 location(s) · Bambino Gesù Hospital and Research Institute · NCT06080191
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.